Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

RARE
Ultragenyx Pharmaceutical Inc.
stock NASDAQ

At Close
Jul 10, 2025 3:59:54 PM EDT
31.03USD-25.109%(-10.41)12,935,297
30.50Bid   31.07Ask   0.57Spread
Pre-market
Jul 10, 2025 9:28:30 AM EDT
33.25USD-19.764%(-8.19)611,666
After-hours
Jul 10, 2025 4:11:30 PM EDT
31.11USD+0.242%(+0.08)9,874
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsMore
open chart   
open chart   
Market Cap
2.93B
CEO
Emil Kakkis
Headquarters
Novato, California, USA
Industry
Biotechnology
Next Earnings
Jul 31, 2025 (21d)
Related
ALXNBMRNFOLDESPRLXRXSPEXALBOXLV
RARE Stats
Avg. Vol. 10 Day
1,310,538
Avg. Vol. 30 Day
1,236,874
Employees
520
Market Cap
2,934,537,495
Shares Out.
94,542,035
On/Off Exchange
54%/46%
6 Month Beta
0.93
1 Year Beta
0.86
2 Year Beta
0.97
3 Year Beta
1.01
52 Week Low
29.59
52 Week High
60.37
SMA50
36.90
SMA200
42.99
1 Week
-22.23%
1 Month
-17.25%
3 Month
-6.40%
6 Month
-26.22%
1 Year
-26.90%
2 Year
-29.70%
5 Year
-64.02%
Profile
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d

RARE Stock Summary

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stock price today is $31.03, and today's volume is 12,935,297. RARE is down -25.109% today. The 30 day average volume is 1,236,874. RARE market cap is 2.93B with 94,542,035 shares outstanding.



Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC